Ventyx Biosciences, Inc. (VTYX) News
Filter VTYX News Items
VTYX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest VTYX News From Around the Web
Below are the latest news stories about VENTYX BIOSCIENCES INC that investors may wish to consider to help them evaluate VTYX as an investment opportunity.
Ventyx Biosciences to Participate in the 35th Annual Piper Sandler Healthcare ConferenceSAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the upcoming 35th Annual Piper Sandler Healthcare Conference. Event: 35th Annual Piper Sandler Healthcare ConferenceLocation: New York, NYDate: Tuesday, November 28, 202 |
Ventyx Biosciences to Participate in the Jefferies London Healthcare ConferenceSAN DIEGO, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the upcoming Jefferies London Healthcare Conference. Event: Jefferies London Healthcare ConferenceLocation: London, United KingdomDate: Thursday, November 16, 2023Time: |
Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate ProgressVentyx to provide updates across clinical-stage portfolio in the first quarter of 2024 Cash, cash equivalents and marketable securities of $300.8 million as of September 30, 2023 SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced financial results for the third qu |
Down -86.57% in 4 Weeks, Here's Why Ventyx Biosciences, Inc. (VTYX) Looks Ripe for a TurnaroundVentyx Biosciences, Inc. (VTYX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
PTON Stock Slumps as Deutsche Bank Downgrades PelotonPeloton stock is taking a beating on Tuesday after shares of PTON were downgraded and saw their price target reduced by Deutsche Bank. |
Why Is Alto Ingredients (ALTO) Stock Down 45% Today?Alto Ingredients stock is falling on Tuesday after the company released a mixed earnings report for the third quarter of the year. |
Why Is Ventyx Biosciences (VTYX) Stock Down 76% Today?Ventyx Biosciences stock is taking a beating on Tuesday after the company announced it will end development of VTX958 on Phase 2 results. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time for another dive into the biggest pre-market stock movers as we break down all of the latest news for Tuesday morning. |
Ventyx Crashes 81% After Scrapping Two Studies On A Psoriasis Treatment FlopVentyx Biosciences scrapped a psoriasis drug that didn't pass muster in Phase 2 testing on Tuesday, and VTYX stock crashed more than 80%. |
Ventyx revises TYK2 drug plans after lackluster study dataThe biotech will terminate studies of its drug in psoriasis and psoriatic arthritis after the “magnitude of efficacy” reported in one was less than Ventyx’s target. |